Mixed-meal tolerance test versus glucagon stimulation test for the assessment of β-cell function in therapeutic trials in type 1 diabetes

Diabetes Care

Volumn 31, Issue 10, 2008, Pages 1966-1971

  Greenbaum, Carla J ^a   Thomas, Mandrup Poulsen ^a   Mcgee, Paula Friedenberg ^a   Battelino, Tadej ^a   Haastert, Burkhard ^a   Ludvigsson, Johnny ^a   Pozzilli, Paolo ^a   Lachin, John M ^a   Kolb, Hubert ^a  

^a TrialNet Publications   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; SUSTACAL; BIOLOGICAL MARKER; DIAGNOSTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CELL FUNCTION; CHILD; CLINICAL TRIAL; FEMALE; GLUCAGON STIMULATION TEST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MIXED MEAL TOLERANCE TEST; NAUSEA; PANCREAS ISLET BETA CELL; PROVOCATION TEST; RANDOMIZATION; REPRODUCIBILITY; SCHOOL CHILD; BLOOD; DIABETIC DIET; DIET RESTRICTION; DIET THERAPY; DRUG EFFECT; MULTICENTER STUDY; ONSET AGE; PATHOPHYSIOLOGY; PHYSIOLOGY; RACE; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGE OF ONSET; BIOLOGICAL MARKERS; C-PEPTIDE; CHILD; CLINICAL TRIALS AS TOPIC; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 1; DIABETIC DIET; FASTING; GLUCAGON; HUMANS; INSULIN-SECRETING CELLS; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY;

EID: 55249085210     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc07-2451     Document Type: Article

References (12)

1. Palmer JP, Fleming GA, Greenbaum CJ. Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve ß-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53:250-264, 2004
2. Greenbaum CJ, Harrison LC: Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 52:1059-1065,2003
3. FDA Guidance for Industry: Diabetes mel-litus: developing drugs and therapeutic bio- logics for treatment and prevention [article online, 2008]. Available from http://www. fda.gov/cder/guidance/7630dft.pdf. Accessed 14 April 2008
4. Demidenko E: Mixed Models: Theory and Applications. New York, John Wiley and Sons, 2004
5. Lachin JM: The role of measurement reliability in clinical trials. Clín Trials 1:553-566, 2004
6. Dunn OJ, Clark V: Correlation coefficients measured on the same individuals. JAmStatAssoc 64:366-377, 1969
7. The DCCT Research Group: Effect of intensive therapy on residual ß-cell function in patients with type I diabetes in the Diabetes Control and Complications Trial. Ann Intern Med 128:517-523, 1998
8. Greenbaum CJ, Prigeon RL, DΆlessio DA: Impaired ß-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. Diabetes 51:951-957, 2002
9. Gjessing HJ, Reinholdt B, Faber OK, Pedersen O: The effect of acute hyperglyce-mia on the plasma C-peptide response to intravenous glucagon or to a mixed meal in insulin-dependent diabetes mellitus. Acta Endocrínol (Copenh) 124:556-562, 1991
10. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Sei-gneurin JM, De Pauw P, Pierard D, Weets I. Rebello P, Bird P, Berrie E, Frewin M, Wald-mann H, BachJF, Pipeleers D, Chatenoud L: Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl ] Med 352:2598-2608, 2005
11. Greenbaum C, Seidel K, Pihoker C: The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes. Diabetes Care 27': 1202-1204, 2004
12. Berger B, Stenstro G, Sundkvist G: Random C-peptide in the classification of diabetes. Scand] Clin Lab Invest 60:687-694, 2000